437 related articles for article (PubMed ID: 30223042)
1. TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis.
Wu J; Zhao W; Zhou B; Su Z; Gu X; Zhou Z; Chen S
Genomics Proteomics Bioinformatics; 2018 Aug; 16(4):276-282. PubMed ID: 30223042
[TBL] [Abstract][Full Text] [Related]
2. TSNAdb v2.0: The Updated Version of Tumor-specific Neoantigen Database.
Wu J; Chen W; Zhou Y; Chi Y; Hua X; Wu J; Gu X; Chen S; Zhou Z
Genomics Proteomics Bioinformatics; 2023 Apr; 21(2):259-266. PubMed ID: 36209954
[TBL] [Abstract][Full Text] [Related]
3. TSNAD and TSNAdb: The Useful Toolkit for Clinical Application of Tumor-Specific Neoantigens.
Wu J; Zhou Z
Methods Mol Biol; 2023; 2673():167-174. PubMed ID: 37258913
[TBL] [Abstract][Full Text] [Related]
4. Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD.
Chen M; Zhang X; Ming Z; Lingyu ; Feng X; Han Z; An HX
J Transl Med; 2024 Mar; 22(1):315. PubMed ID: 38539235
[TBL] [Abstract][Full Text] [Related]
5. A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets.
Chen C; Zhou Q; Wu R; Li B; Chen Q; Zhang X; Shi C
Biomed Res Int; 2019; 2019():2183510. PubMed ID: 31781598
[TBL] [Abstract][Full Text] [Related]
6. DeepHLApan: A Deep Learning Approach for Neoantigen Prediction Considering Both HLA-Peptide Binding and Immunogenicity.
Wu J; Wang W; Zhang J; Zhou B; Zhao W; Su Z; Gu X; Wu J; Zhou Z; Chen S
Front Immunol; 2019; 10():2559. PubMed ID: 31736974
[TBL] [Abstract][Full Text] [Related]
7. GNIFdb: a neoantigen intrinsic feature database for glioma.
Li W; Sun T; Li M; He Y; Li L; Wang L; Wang H; Li J; Wen H; Liu Y; Chen Y; Fan Y; Xin B; Zhang J
Database (Oxford); 2022 Feb; 2022():. PubMed ID: 35150127
[TBL] [Abstract][Full Text] [Related]
8. Identification of shared neoantigens in esophageal carcinoma by the combination of comprehensive analysis of genomic data and in silico neoantigen prediction.
Yuan Y; Chen C; Liu S; Xiong H; Huang Y; Zhang X; Zhang X; Li B
Cell Immunol; 2022 Jul; 377():104537. PubMed ID: 35636066
[TBL] [Abstract][Full Text] [Related]
9. Population-level distribution and putative immunogenicity of cancer neoepitopes.
Wood MA; Paralkar M; Paralkar MP; Nguyen A; Struck AJ; Ellrott K; Margolin A; Nellore A; Thompson RF
BMC Cancer; 2018 Apr; 18(1):414. PubMed ID: 29653567
[TBL] [Abstract][Full Text] [Related]
10. dbPepNeo: a manually curated database for human tumor neoantigen peptides.
Tan X; Li D; Huang P; Jian X; Wan H; Wang G; Li Y; Ouyang J; Lin Y; Xie L
Database (Oxford); 2020 Jan; 2020():. PubMed ID: 32090262
[TBL] [Abstract][Full Text] [Related]
11. NEPdb: A Database of T-Cell Experimentally-Validated Neoantigens and Pan-Cancer Predicted Neoepitopes for Cancer Immunotherapy.
Xia J; Bai P; Fan W; Li Q; Li Y; Wang D; Yin L; Zhou Y
Front Immunol; 2021; 12():644637. PubMed ID: 33927717
[TBL] [Abstract][Full Text] [Related]
12. MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design.
Cai W; Zhou D; Wu W; Tan WL; Wang J; Zhou C; Lou Y
BMC Genomics; 2018 Aug; 19(1):582. PubMed ID: 30075702
[TBL] [Abstract][Full Text] [Related]
13. Identification of Mutated Peptides in Bladder Cancer From Exomic Sequencing Data Reveals Negative Correlation Between Mutation-Specific Immunoreactivity and Inflammation.
Wang C; Ding Y; Liu Y; Zhang Q; Xu S; Xia L; Duan H; Wang S; Ji P; Huang W; Zhao G; Cao Z; Shen H; Wang Y
Front Immunol; 2020; 11():576603. PubMed ID: 33329543
[TBL] [Abstract][Full Text] [Related]
14. PSSMHCpan: a novel PSSM-based software for predicting class I peptide-HLA binding affinity.
Liu G; Li D; Li Z; Qiu S; Li W; Chao CC; Yang N; Li H; Cheng Z; Song X; Cheng L; Zhang X; Wang J; Yang H; Ma K; Hou Y; Li B
Gigascience; 2017 May; 6(5):1-11. PubMed ID: 28327987
[TBL] [Abstract][Full Text] [Related]
15. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
16. COSMIC-based mutation database enhances identification efficiency of HLA-I immunopeptidome.
Wang F; Zhang Z; Mao M; Yang Y; Xu P; Lu S
J Transl Med; 2024 Feb; 22(1):144. PubMed ID: 38336780
[TBL] [Abstract][Full Text] [Related]
17. Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies.
Lo AA; Wallace A; Oreper D; Lounsbury N; Havnar C; Pechuan-Jorge X; Wu TD; Bourgon R; Jones R; Krogh K; Yang GY; Zill OA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599029
[TBL] [Abstract][Full Text] [Related]
18. Applications of Immunogenomics to Cancer.
Liu XS; Mardis ER
Cell; 2017 Feb; 168(4):600-612. PubMed ID: 28187283
[TBL] [Abstract][Full Text] [Related]
19. HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer.
Ren Y; Cherukuri Y; Wickland DP; Sarangi V; Tian S; Carter JM; Mansfield AS; Block MS; Sherman ME; Knutson KL; Lin Y; Asmann YW
Oncoimmunology; 2020; 9(1):1744947. PubMed ID: 32523802
[TBL] [Abstract][Full Text] [Related]
20. [A new bioinformatics approach for prediction of potential tumor neoantigens based on the cancer genome atlas dataset].
Huang C; Ma J; Wu C; Zhu Y
Sheng Wu Gong Cheng Xue Bao; 2019 Jul; 35(7):1295-1306. PubMed ID: 31328486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
